<p><i>NLRP3</i> mosaicism is a well-established mechanism causing the monogenic autoinflammatory disease named cryopyrin-associated periodic syndromes (CAPS). The number of reported patients with <i>NLRP3</i> mosaicism is small, and the knowledge about the long-term disease behavior is limited. Herein we assembled the largest cohort of individuals with <i>NLRP3</i> mosaicism reported to date to obtain additional evidence that strengthens the understanding of this disease. The novel genetic data were obtained by using Sanger and next-generation sequencing methods, whereas i<i>n vitro</i> analyses determined the functional consequences of detected variants. A total of seventeen individuals with <i>NLRP3</i> mosaicism were enrolled, with 16/17 experiencing different CAPS phenotypes. An overrepresentation of late-onset forms was detected (37.5%). Overall, clinical manifestations, analytical results, and outcomes of treatments were markedly similar to those detected in patients with germline variants. A large mutational diversity was identified, with 16 different variants among 17 individuals. Two main patterns of mosaicism (extended vs. myeloid-restricted) were detected, with the last one overrepresented in the late-onset group. The evaluation of mosaicism over time identified three different patterns, being the group with stable mosaicism the largest one. Collected evidence supports the marked similarities among patients carrying somatic or germline <i>NLRP3</i> variants. The overrepresentation of <i>NLRP3</i> mosaicism in late-onset forms should be considered in patients with inflammatory manifestations starting in adulthood. Analysis of mosaicism at the biological level confirms the two known patterns of corporal distribution and reveals that mosaicism remains stable over time in most patients, but it may also vary during the course of the disease.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Novel Insights into the Clinical Features, Genetic Spectrum and Clonal Evolution of Patients Carrying NLRP3 Mosaicism

  • Nuria Bonet,
  • Jose M. Mascaro Jr,
  • Laura Hurtado-Navarro,
  • Diego Angosto-Bazarra,
  • Jose Luis Callejas-Rubio,
  • Daniel Clemente,
  • Alejandro Souto,
  • Olalla Lima,
  • Natalia Palmou-Fontana,
  • Eulalia Baselga,
  • Santiago Jiménez-Treviño,
  • Agustin Remesal,
  • Marta Andreu-Barasoain,
  • Luis Fernandez-Dominguez,
  • Josep Riera-Monroig,
  • Maria Aparicio,
  • Juan Garcia-Herrero,
  • David Pesqué,
  • Maria Teresa Sanchez-Calvin,
  • Jose Miguel Lezana-Rosales,
  • Maria Correyero-Plaza,
  • Julio Garcia-Villalba,
  • Victor Bolaño,
  • Sara Peiro,
  • Mar Diaz,
  • Alexandru Vlagea,
  • Daniel Lorca,
  • Virginia Fabregat,
  • Maria Carmen Anton,
  • Susana Plaza,
  • Luis Ignacio Gonzalez-Granado,
  • Concepción Postigo,
  • Jose Maria Garcia-Ruiz de Morales,
  • Enrique Gómez de la Fuente,
  • Estibaliz Iglesias,
  • Javier Gomez-Roman,
  • Caritina Vázquez-Triñanes,
  • Juan Carlos Lopez-Robledillo,
  • Norberto Ortego-Centeno,
  • Ana María Giménez-Arnau,
  • Josep M. Campistol,
  • Hafid Laayouni,
  • Iñaki Ortiz de Landazuri,
  • Jordi Yagüe,
  • Eva Gonzalez-Roca,
  • Anna Mensa-Vilaro,
  • Oscar Fornas,
  • Eduardo Ramos,
  • Pablo Pelegrin,
  • Ferran Casals,
  • Juan I. Arostegui

摘要

NLRP3 mosaicism is a well-established mechanism causing the monogenic autoinflammatory disease named cryopyrin-associated periodic syndromes (CAPS). The number of reported patients with NLRP3 mosaicism is small, and the knowledge about the long-term disease behavior is limited. Herein we assembled the largest cohort of individuals with NLRP3 mosaicism reported to date to obtain additional evidence that strengthens the understanding of this disease. The novel genetic data were obtained by using Sanger and next-generation sequencing methods, whereas in vitro analyses determined the functional consequences of detected variants. A total of seventeen individuals with NLRP3 mosaicism were enrolled, with 16/17 experiencing different CAPS phenotypes. An overrepresentation of late-onset forms was detected (37.5%). Overall, clinical manifestations, analytical results, and outcomes of treatments were markedly similar to those detected in patients with germline variants. A large mutational diversity was identified, with 16 different variants among 17 individuals. Two main patterns of mosaicism (extended vs. myeloid-restricted) were detected, with the last one overrepresented in the late-onset group. The evaluation of mosaicism over time identified three different patterns, being the group with stable mosaicism the largest one. Collected evidence supports the marked similarities among patients carrying somatic or germline NLRP3 variants. The overrepresentation of NLRP3 mosaicism in late-onset forms should be considered in patients with inflammatory manifestations starting in adulthood. Analysis of mosaicism at the biological level confirms the two known patterns of corporal distribution and reveals that mosaicism remains stable over time in most patients, but it may also vary during the course of the disease.